newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

  • DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced that President & CEO Rick Pauls will attend the Jefferies Global Healthcare Conference in London from November 17-20, 2025.
  • Mr. Pauls will deliver a corporate presentation on Thursday, November 20, 2025, from 10:00-10:25 AM GMT & participate in one-on-one investor meetings.
  • DiaMedica is a clinical-stage biopharmaceutical company focused on developing treatments for preeclampsia, fetal growth restriction, & acute ischemic stroke.
  • The company's lead candidate, DM199, is the first pharmaceutically active recombinant form of the KLK1 protein clinically studied in the United States.
  • Human-derived KLK1 is an established therapeutic modality in China for treating acute ischemic stroke & other vascular diseases.